Oncology News Central
@OncNewsCentral
Oncology News Central (ONC) is the single destination for oncologists to stay abreast of the rapidly changing oncology landscape.
Over 35% of physicians have considered leaving medicine in 2025, driven by #Burnout & clinical demands—especially in #CriticalCare, ER, hospital medicine, #FamilyMedicine, #Cardiology, & #Psychiatry. Where does your speciality rank? bit.ly/408tjVY @ACPIMPhysicians @aafp

From “radical transparency” to leadership shifts, safety alerts, & a staff exodus—@FDA headlines are reshaping drug regulation. Most shocking? >150 drugs allowed in via exempted foreign plants w/ major safety issues. bit.ly/4kVVaAl #DrugSafety @MartyMakary @propublica
#PancreaticCancer momentum: Fast Track designations for EBC-129 (#ADC) & nadunolimab (anti-IL1RAP) signal promise. CAN04 study: OS 14.2 mo, ORR 48%. NAPOLI-3 hits 19.5 mo median OS—frontline strategies are evolving rapidly. Tap for more: bit.ly/4nbqLQZ @IARCWHO
“Attention to bone health should start at the very beginning—at the time of myeloma diagnosis,” says @amangodaramd of @huntsmancancer. With 70–80% of patients presenting with bone damage, early intervention is critical. bit.ly/43UWuy8 #MMSM #MultipleMyeloma
NCI in turmoil: Staff layoffs, a proposed 40% budget cut, & CRL quotes like “People will die” and “It’s a crap show” show how serious the internal chaos is. Insiders warn: this could “destroy clinical research.” bit.ly/46WpirO #CancerResearch #NCI #Oncology @theNCI
Satri-cel in Solid Tumors: In a world-first RCT for #CARTCellTherapy in solid cancer, CLDN18.2-targeted satri-cel doubled PFS vs standard tx in advanced gastric/GEJ cancer (3.25 vs 1.77 mo; HR 0.37; P<.0001). bit.ly/3H4c3uJ #GastricCancer #GEJCancer @TheLancet
FDA declines approval of RP1 + nivolumab for advanced #Melanoma—despite 31% ORR in IGNYTE Phase 1/2. FDA cites efficacy & trial design concerns in CRL, underscoring need for rigorously controlled confirmatory trials. bit.ly/3TX6iBZ #Immunotherapy @JCO_ASCO
#UrothelialCarcinoma still lacks predictive biomarkers that guide treatment. @shilpaonc argues #ctDNA shows real promise—especially for therapy de-escalation. “We may be overtreating patients post-surgery. We need real-time tools.” bit.ly/3IEnV7b #BladderCancer
#SERENA6: Switching to camizestrant at molecular progression (via #ctDNA) delayed disease worsening in #ESR1+ breast cancer. Dr Brufsky: “It’s practice-changing—but not for everyone. We need to find out who.” bit.ly/4m1HfJW #ASCO25 #BreastCancer #BCSM @UPMCHillmanCC
#EHR alerts + bundled interventions = lower 30-day readmits & shorter LOS for high-risk metastatic cancer patients. Real-world proof that digital tools & care coordination make a measurable difference.➜ bit.ly/44os9bC #Oncology #EHR #DigitalTech @dapattmd @JCOOP_ASCO
CMMI’s WISeR pilot brings prior auth to traditional #Medicare—for now, non-oncology services only. But experts warn: expansion could follow. “Red flags go up,” says @oncologyCOA's @TedOkon. bit.ly/3TVMAGK #Oncology #Medicare #PriorAuth @CMSinnovates
#CancerCare is in a payer-pharma tug of war—& oncologists are caught in the middle. Key drugs like #Keytruda now cost more than all of #Radiotherapy combined. Burdened clinicians need real solutions, not just audits. bit.ly/3IHhz7e #Oncology @JohnsonRebeccaM @ASTRO_org
Need a summer book recommendation? @ramsedhom enjoyed 'Think Again' by Adam Grant—a powerful case for rethinking assumptions in fast-moving, human-centered fields like oncology. Must-reads here: bit.ly/4lP0pmQ #SummerReads #PhysicianWellness @AdamMGrant @ShirishGadgeel
“Thrombosis = leading preventable noncancer cause of death in patients on systemic cancer therapy,” says Dr Calverley. Yet VTE/ATE often go unreported in trials. Time for uniform, mandatory reporting. bit.ly/415P4WR #Thrombosis #ClinicalTrials @OHSUNews @JCO_ASCO
Pembrolizumab & nivolumab indications for gastric, #GEJ & #EsophagealCancers are now limited to PD‑L1 ≥ 1 (and ≥10 for certain pembrolizumab settings), following @FDA's review of #CheckMate649 & #KEYNOTE859 data. bit.ly/3FU00zE #GastricCancer
#TumorBoards: critical for complex #CancerCare—but when poorly run, they waste precious time. Oncologist Miguel Borregón, MD, calls for “rational resource management.” How can we make tumor boards work better?➜ bit.ly/4lkwIK7 #Oncology @GVAsaludelche @JCOOP_ASCO
💸 “Financial toxicity” isn’t just about #CancerTreatment — it’s blocking patients from trials, too. On average: $600–$1,500/month in non-medical costs (travel, lodging, lost wages). bit.ly/45SmifK #ClinicalTrials @LUNGevity @utswcancer @JCO_ASCO
#ASCO25 Update: One-third of triple-class refractory #Myeloma patients remain progression-free at 5 years post–cilta-cel. Is this a functional cure—or the strongest remission yet? bit.ly/4dVMpUV #MultipleMyeloma #CAR_T @LevineCancer
#KEYNOTE689: Adding #Pembrolizumab before and after surgery significantly improves EFS in resectable LA-HNSCC. A potential new standard of care after 20+ years of stagnation. bit.ly/4cVzF0j #LARVOL #AACR25 #HNSCC #CancerResearch @DrUppaluri
INAVO120 #ASCO25: Inavolisib + palbo/fulv boosted OS by 7mo & doubled PFS in 1L PI3K-mut HR+/HER2- MBC — but w/ more toxicity. Testing & AE management key. bit.ly/3GDHwDK #BreastCancer #BCSM #MetastaticBreastCancer @DrSGraff @ErinCobain @WinshipAtEmory @royalmarsdenNHS
A novel CAR-T (CHM CDH17) for gastroenteropancreatic #Neuroendocrine tumors. SGR-1505, a MALT1 inhibitor, for Waldenström macroglobulinemia after ≥2 prior lines. Early-phase signals, big unmet needs. bit.ly/46p7vcC #CancerResearch #HemOnc #CarTCellTherapy
